CARDIOPROGRESS
Foundation for the advancement of cardiology

Ventricular Changes Seem Worse in Persistent vs Paroxysmal AF The study covered in this summary was published on ResearchSquare.org as a preprint and has not yet been peer reviewed.

No Thrombotic Risk From Higher Lp(a) Levels Contrary to indications from previous studies, there is no association between increased lipoprotein(a) concentrations and the risk for subsequent thrombotic events, suggests a new large-scale analysis. (Milan)

Noninvasive Approach to Revascularization Decisions Shows Promise When deciding on the optimal revascularization strategy for patients with multivessel coronary disease, a noninvasive approach using quantitative flow ratio (QFR) showed substantial agreement with the more invasive classical fractional flow reserve (FFR) approach in a new study.

SAFE-PAD Shows Long-Term Safety of Paclitaxel Devices Patients who have paclitaxel-coated stents and balloons have survival and outcomes comparable to those who have a bare-metal stent or percutaneous transluminal angioplasty, according to updated results from a large study of almost 170,000 Medicare beneficiaries.

ADT for Prostate Cancer: What's the Risk on the Heart? Androgen deprivation therapy (ADT) for localized prostate cancer increases the risk of myocardial infarction (MI), stroke, and other cardiovascular disease (CVD) events as well as death, according to a study from Norway.

Genetic Test for Six Chronic Diseases Undergoing Clinical Trial A new type of genetic test known as a polygenic risk score could change the way clinicians detect and treat chronic illnesses. But to be widely used, genomic findings in large populations first need to be translated into valid clinical tests for individual patients. Then physicians need meaningful interpretations of test data to help make clinical decisions about patient care.

Greater Triglyceride-Glucose Index Variability Tied to CV Risk The study covered in this summary was published on ResearchSquare.com as a preprint and has not yet been peer reviewed.

Smokers With Heart Disease Could Gain 5 Years by Quitting Smoking cessation appears to be comparable to the use of three targeted drugs in warding off future major cardiovascular events in smokers with atherosclerotic cardiovascular disease (ASCVD), according to a new study.

FDA Approves Fitbit's AFib-Detection Software A popular fitness tracker company has received approval from the Food and Drug Administration for a new software algorithm to detect atrial fibrillation (AFib), Fitbit announced on April 11.

The Uphill Struggle for High-Intensity Statins in ASCVD Patients New research suggests physicians face a Herculean task to get Americans with atherosclerotic cardiovascular disease (ASCVD) to take high-intensity statins, despite multiple professional guidelines giving the therapy their highest level recommendation.

FDA Okays IN.PACT 018 Drug-Coated Balloon for PAD The US Food and Drug Administration has approved the IN.PACT 018 drug-coated balloon (DCB) for the treatment of peripheral arterial disease, Medtronic announced today.

World Heart Summit 2022 THE SUMMIT WILL CONVENE WORLD LEADERS IN CARDIOVASCULAR HEALTH IN THE HEART OF GLOBAL HEALTH DIPLOMACY, JUST AHEAD OF THE 75TH WORLD HEALTH ASSEMBLY. Now in its 7th edition, the World Heart Summit will take place on 21-22 May 2022, just two days ahead of the World Health Assembly, under the timely and universal theme of Cardiovascular Health for Everyone.

New ACC Guidance on Cardiovascular Consequences of COVID-19 The American College of Cardiology (ACC) has issued an expert consensus clinical guidance document for the evaluation and management of adults with key cardiovascular consequences of COVID-19. The document makes recommendations on how to evaluate and manage COVID-associated myocarditis and long COVID and gives advice on resumption of exercise following COVID-19 infection.

THE CONTRIBUTION OF SOVIET HEALTHCARE WORKERS TO THE VICTORY IN THE SECOND WORLD WAR It is difficult to overestimate the contribution of healthcare workers to the Victory in the Second World War. The losses in the war could have been more devastating if not for the courage of people were fighting for the lives of the wounded and sick on the battlefields. Over 200,000 doctors and a half-million army of paramedics worked at the front and in the rear.

Lowering BP According to Newest Guidance Would Cut CV Events Using the 2021 Kidney Disease: Improving Global Outcomes (KDIGO) guideline target of systolic blood pressure (BP) < 120 mm Hg, 66% of adults with chronic kidney disease (CKD) would be eligible for BP lowering, according to a study from South Korea.

Distress-Related Metabolite Levels Predicts Future Cardiovascular Events A metabolite-based distress score derived from measurements of molecular biomarkers in women related to chronic distress can predict future risk for cardiovascular disease. The study covered in this summary was published in medRxiv.org as a preprint and has not yet been peer reviewed.

Ending Rheumatic Heart Disease is achievable if we put our heads and minds to it Preventable, yet persistent, Rheumatic Heart Disease (RHD) is the most commonly acquired heart disease in people under 25 years of age. The World Heart Federation (WHF) is committed to the fight to ensure cardiovascular health for everyone. Through WHF’s network of Members and the power of personal testimonials, we are spreading awareness that RHD can be prevented, diagnosed, and treated. This editorial was authored by WHF Director of Policy and Advocacy Jeremiah Mwangi and was first published in FORESIGHT Global Health on 19 August 2021.

Dear colleagues! I welcome you on behalf of the Organizing Committee of the XI International Forum for Cardiology and Internal Medicine, which will be held from March 22 to 24, 2022 in Moscow.

Polypill Shows LDL-Lowering Advantage in High-risk Primary Prevention Patients: VULCANO Key Takeaways The CNIC (Centro Nacional de Investigaciones Cardiovasculares) polypill contains acetylsalicylic acid (100 mg), atorvastatin (30 mg or 40 mg), and ramipril (2.5 mg, 5 mg, or 10 mg), and is the only polypill for cardiovascular disease (CVD) currently marketed in European countries.

Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association The American Heart Association, in conjunction with the National Institutes of Health, annually reports the most up-to-date statistics related to heart disease, stroke, and cardiovascular risk factors, including core health behaviors (smoking, physical activity, diet, and weight) and health factors (cholesterol, blood pressure, and glucose control) that contribute to cardiovascular health.